Precigen (PGEN) Cash & Equivalents (2012 - 2026)

Precigen (PGEN) has reported Cash & Equivalents for 15 consecutive years, with $7.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 23.47% year-over-year to $7.5 million; the TTM figure through Mar 2026 stood at $7.5 million (up 23.47% YoY), while the FY2025 annual figure was $30.2 million, up 2.43% from the prior year.
• Cash & Equivalents declined to $7.5 million in Q1 2026 per PGEN's latest filing, from $30.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $43.8 million in Q2 2022 and bottomed at $4.9 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $17.3 million across 5 years, with a median of $13.8 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 78.27% — and 2024, when it surged 289.51%.
• Precigen's Cash & Equivalents stood at $4.9 million in 2022, then soared by 55.99% to $7.6 million in 2023, then soared by 289.51% to $29.5 million in 2024, then increased by 2.43% to $30.2 million in 2025, then sank by 75.26% to $7.5 million in 2026.
• Business Quant data shows PGEN's Cash & Equivalents at $7.5 million in Q1 2026, $30.2 million in Q4 2025, and $14.3 million in Q3 2025.